European Investment Bank
The European Investment Bank (EIB), established in 1958, is a long-term lending institution owned by the EU Member States. Headquartered in Luxembourg, it offers a wide range of financing solutions, including project loans, loans to banks and intermediaries, venture capital funds, and equity investments. EIB also provides structured finance products, guarantees, and securitization instruments, along with advisory services for infrastructure projects, urban development, and small to medium-sized enterprises. Its portfolio is predominantly composed of loans (93.08%), with a small portion allocated to debt and fixed income, shares, and other assets. EIB's mission is to support European integration and social cohesion, primarily within the European Union and internationally.
Norlase
Debt Financing in 2025
Norlase is a developing global ophthalmic medical device company focused on creating innovative laser solutions for the treatment of retinal and glaucoma diseases. The company has introduced advanced ophthalmic laser technologies, including ECHO and LEAF. ECHO is notable for being the world's first truly portable pattern laser, featuring battery power and a wireless user interface with voice control, which enhances its portability and flexibility during treatments. LEAF is an ultra-compact green laser photocoagulator that conveniently attaches to existing slit lamps, thus simplifying laser procedures by eliminating the need for external fibers or extra equipment. Norlase aims to provide affordable access to powerful laser technologies for effective patient care.
Blickfeld
Debt Financing in 2022
Blickfeld GmbH, established in 2017 and based in Munich, Germany, specializes in the production of LiDAR sensors and associated software. These sensors, based on patented silicon MEMS mirrors and commercial off-the-shelf components, measure direct distance information in 3D, enabling autonomous vehicles to perceive and analyze their surroundings. The company's object detection and mapping software processes data from these sensors, facilitating applications in city planning, connected mobility, real-time mapping, and usage pattern analysis. Blickfeld caters to the automotive, transportation, industrial, and robotics sectors, offering low-cost LiDAR systems to support the mass market's transition towards autonomous mobility and IoT applications.
DyeMansion
Venture Round in 2022
DyeMansion GmbH, established in Munich, Germany in 2013, specializes in post-processing and coloring of 3D-printed laser sintered parts. The company offers high-volume finishing systems that transform raw, 3D-printed parts into high-value consumer and industrial products, such as eyewear, automotive components, and medical devices. DyeMansion works with major 3D printing systems like EOS, HP, and 3D Systems, enabling precision coloring and finish to exact specifications. With over 400 customers, including leading global manufacturers, DyeMansion has become the global leader in additive manufacturing finishing systems for 3D-printed polymer parts.
Nanobiotix SA is a clinical-stage nanomedicine company based in Paris, France, focused on innovative cancer treatments. Founded in 2003, the company develops NanoXray products designed to enhance the effectiveness of radiotherapy by increasing the impact on tumor cells while minimizing exposure to surrounding healthy tissues. One of its primary offerings is NBTXR3, a radio-enhancer composed of hafnium oxide, which targets various solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma. In addition to NBTXR3, Nanobiotix is also involved in research programs exploring the use of magnetic particles and laser-activated nanoparticles for cancer treatment and diagnostics.
Nanobiotix SA is a clinical-stage nanomedicine company based in Paris, France, focused on innovative cancer treatments. Founded in 2003, the company develops NanoXray products designed to enhance the effectiveness of radiotherapy by increasing the impact on tumor cells while minimizing exposure to surrounding healthy tissues. One of its primary offerings is NBTXR3, a radio-enhancer composed of hafnium oxide, which targets various solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma. In addition to NBTXR3, Nanobiotix is also involved in research programs exploring the use of magnetic particles and laser-activated nanoparticles for cancer treatment and diagnostics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.